Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
Oct 4 LLY Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
Oct 4 LLY Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
Oct 4 LLY Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Oct 4 PFE Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Oct 4 LLY What end of Eli Lilly's weight-loss drug shortage means for the competition
Oct 4 LLY Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
Oct 4 LLY England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
Oct 4 PFE Pfizer Inc. (NYSE:PFE) is largely controlled by institutional shareholders who own 67% of the company
Oct 4 LLY AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
Oct 4 LLY NHS proposes phased launch for Eli Lilly’s Mounjaro
Oct 4 PFE As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Oct 4 LLY As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Oct 4 LLY Top T. Rowe Price Fund Manager Shares Her Secrets
Oct 4 LLY Texas sues major PBMs, pharma companies over high insulin prices
Oct 4 LLY Ozempic for all, Zepbound is back, and the top CEO pay: Pharma news roundup
Oct 3 LLY Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
Oct 3 LLY Top Research Reports for Exxon Mobil, Mastercard and Procter & Gamble
Oct 3 LLY Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Oct 3 LLY For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
Oct 3 LLY Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags